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DESPITE advances in surgical technique and radiotherapy the prospect of a
cure for the majority of patients with cancer of the head and neck remains
extremely small. Even under the most favourable circumstances little improve-
ment can be expected from surgery alone, and although radiotherapy still plays
a dominant role in the treatment of cancer in certain sites, such as the naso-
pharynx, the general outlook is depressing.
In recent years, an intensive search has been in progress for means whereby
the prognosis for cancer of the head and neck might be improved, the emphasis
being directed towards the development and usage ofa variety ofchemotherapeutic
agents. This paper is an account of eighty patients with advanced neoplasms
of the head and neck who have been treated with two cytotoxic preparations,
ethoglucid and cyclophosphamide, during the period September 1961 to September
1963. The majority of these cases had already received treatment by orthodox
techniques but the tumour had either failed to respond or had recurred, a positive
biopsy being obtained in every case. By definition the tumour lay above the
clavicle excluding the cranial contents.
Previous Literature
Since earliest times attempts have been made to destroy superficial cancers
by the topical application of a wide variety of preparations.
Present day cancer chemotherapy probably dates from the observations of
Gilman and Philips in 1946 that mustard compounds caused regression of not
only certainly experimental tumours but also human lymphosarcoma and Hodg-
kin's disease. Clinical trials were started the following year (Jacobson et al.,
1946) and encouraging reports appeared in 1946 (Goodman et al., 1946; Rhoads
et al., 1946). These compounds were administered systemically and it soon,
became apparent that although regression of the tumour mass often occurred
the mustards were not tumour specific and appeared to exert their greatest effect
upon rapidly growing tissues. Even in doses exhibiting no tumour inhibiting
effect, serious damage to bone marrow and gastro-intestinal tract occurred and this
reduced the amount of the drug that could be safely administered.
In an attempt to minimise toxicity and yet increase the tumoricidal action,
intra-arterial administration of nitrogen mustard was investigated (Klopp et al.,
1950; Bierman et al., 1951 ; Sullivan et al., 1953). Unfortunately leakage of
the drug into the systemic circulation continued to produce serious marrowCHEMOTHERAPY IN HEAD AND) NECK CANCER
depression. Intra-arterial injection produced vascular thrombosis and it was
necessary to administer only small doses. Creech (1958) attempted to overcome
these problems by isolating the tumour bearing area from the systemic circulation
and then perfusing the tumour blood supply with a pump oxygenator system.
Using this technique, obviously feasible for only certain tumours, it proved
possible to administer large doses of cytotoxic agents to the tumour area without
producing serious side effects. Many reports appeared using this method of
regional perfusion, (Creech et al., 1959; Krementz et al., 1959, 1960 ; Reemtsma
et al., 1959; Austen et al., 1959; Hickey et al., 1959; Knock, 1959; Sullivan,
Mliller and Sikes, 1959; Woodhall et at., 1959; Pierpont and Blades, 1960:
Shingleton et al., 1959; Cooling, Garai and Staunton, 1962; Stehlin et al., 1960).
However this technique is difficult to apply to the head and neck. Cannula-
tion of the carotid artery with return through the internal jugular vein ignores
the extensive vertebral venous system and there is consequently serious leakage
into the systemic circulation.
Sullivan et al., in 1959, described regional perfusion of the head and neck using
the anti-metabolite methotrexate. Unfortunately single daily intra-arterial
administration ofthis drug resulted in toxic side effects similar to those experienced
with systemic dosage. However by giving the specific metabolite citrovorum
factor systemically and the anti-metabolite by continuous intra-arterial infusion
a markedly enhanced anti-tumour effect was obtained with minimal systemic
toxicity. Many reports on the use of this technique have appeared in the litera
ture (Westbury, 1963; Milnes Walker, Espiner and Vowles, 1962; Nahum and
Roehlin, 1963), but although immediate regression of the tumour is obtained
in most cases, this improvement is rarely maintained. There is also considerable
morbidity and mortality associated with the introduction of indwelling intra-
arterial catheters and with prolonged intra-arterial infusion especially in the
older age group. In view of the poor long term results and the complications
associated with this technique, it would appear to be no longer justifiable in the
management of advanced head and neck cancer.
SELECTION OF PATIENTS
The decision to treat any patient with a new, and potentially lethal form of
therapy, must only be taken after serious consideration of each individual case.
No patient suffering from cancer has as yet been cured by chemotherapy and the
most that can be anticipated is complete regression of the tumour for months or
years.
In selecting patients for chemotherapy our task has been simplified by the
fact that all except eight had previously been treated by radical surgery or radio-
therapy. Persistence or recurrence of disease indicated that the cancer was in-
curable and any therapy which could ameliorate discomfort or suffering appeared
justifiable.
Of the eight previously untreated cases, three were very advanced when
first seen. The remainder included a melanoma of the nasal septum, lethal
midline granuloma of the face, generalised lymphosarcomatosis, rhabdomyo-
sarcoma of the middle ear and an elderly man with a large carcinoma of the pyri-
form fossa who had refused orthodox treatment. Details of the age, site of
neoplasm and histology are given in Table I.
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CHOICE OF CHEMOTHERAPEUTIC AGENT
At present two main groups ofcytotoxic agents are available for the treatment
of head and neck malignancies-the alkylating agents and the anti-metabolites.
The former are generally toxic to all cells and are potent mutagenic agents. In
many ways alkylating agents and ionizing radiations appear to produce similar
biological effects.
However, different alkylating agents may vary in their effect upon a given
tissue although these variations are possibly only quantitative, dependant upon
the rate of alkylation with cell nucleic acids.
Anti-metabolites on the other hand act as competitive inhibitors of essential
metabolic processes. Those most used in cancer chemotherapy are the anti-
folic acid compounds and the purine and pyrimidine substances. The inhibition
of the synthesis of nucleic acid would seem to be a logical attack against the neo-
plastic cell. Unfortunately published results indicate that an initially favourable
response is rarely maintained, and the agent needs to be applied to the neoplastic
cell for long periods in order to exert an effect upon fresh generations of dividing
cells. Drug resistance invariably occurs, possibly due to the malignant cell
utilising alternative pathways for the synthesis of essential metabolites.
In view ofthe disappointing results reported using the anti-metabolite metho-
trexate in head and neck cancer, it was decided to confine our therapy to the
alkylating agents, ethoglucid and cyclophosphamide.
The best known alkylating agent is ofcourse nitrogen mustard but the limiting
factors in its use are its haematological toxicity, low therapeutic index and its
non selective site of activity (Gilman and Philips, 1946). A report circulated in
1960 by A. L. Walpole (1960, personal communication) detailed the effect of a
bis-epoxide, triethyleneglycol diglycidyl ether upon the Walker carcinoma 256
in rats. The experimental results were so striking in comparison with other
alkylating agents that although appreciating the dangers of applying such results
to human cancer, it was decided to use this compound for intra-arterial infusion
in clinical neoplasms.
In many instances, however, local invasion or wide dissemination of a cancer
makes regional intra-arterial infusion impracticable. For these cases cyclopho-
sphamide was chosen, since it could be given by mouth and was inactive until
the active radical is liberated at sites of high phosphatase and phosphamidase
concentrations-as was thought to exist in tumour cells.
A. ETHOGLUCID (TRIETHYLENEGLYCOL DIGLYCIDYL ETHER)
Inhibition of growth of the Walker tumour in rats by certain bis-epoxides
given intra-peritoneally, was reported by Hendrey et al. in 1951. Development of
this work showed that the bis-epoxide resorcinol diglycidyl when given intra-
venously had a marked inhibitory effect upon tumour growth, causing cytological
changes of a radiometric type in both tumour and bone marrow. Walpole
(personal communication) reported on the effect of triethyleneglycol diglycidyl
ether on the Walker tumour in rats. Intravenous injection starting 24 hours
after implantation caused complete suppression of tumour development in a
significant proportion of the animals. Complete regression also occurred in
tumours already established for five to six days-a unique occurrence.
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Physical and chemical properties
In the pure state ethoglucid is a colourless liquid-specific gravity 1 13,
miscible in all proportions with water and most organic solvents. It solidifies
at low temperatures and melts between -15° C. and -11 C. Chemically it is
highly reactive, giving in general addition products with acids and polymers with
bases. Even when pure it appears to polymerise slowly and should be kept below
0° C.
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FIGc. 1.-Venous blood levels of ethoglucid following intravenous administration of 250 mg./kg
Distribution and metabolism
A method for the estimation of the compound in blood and tissues has been
developed by Imperial Chemical Industries, Ltd., using p-hydroxyazobenzene
p-sulphonic acid as a reagent. The rapid removal of ethoglucid from the blood
is typical of alkylating agents and indicates that the drug is being localised in
the tissues before being metabolically degraded. The results after intravenous
(Fig. 1) and intra-arterial injection (Fig. 2) in man shows a metabolic half-life
of 10-15 minutes. Ethoglucid has been shown to be present in large amounts
in all the organs of the rat, except the liver, kidney, lung and ovary-after an
intravenous injection of 300 mg./kg. There is free diffusion into the C.S.F. and
human tumours can be seen to " wet " after intra-arterial injection.
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Excretion of unchanged ethoglucid in the urinie is negligible and tissue binding
of the drug does not appear to be an important feature. MIetabolic degradation
is therefore, the only way of accounting for the rapid disappearance of tlhe drug.
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FIG. 2.-Venous
MINUTES
loo0( levels of ethoglucid following intra-arterial administration of 250 mg.,/kg.
Toxicity
(a) Local toxic effects
Ethoglucid has only been given intra-arterially in this series of patients.
Dosage is between 50 and 250 mg./kg. and the drug is diluted with normal saline.
No incidence of vascular spasm or thrombosis has occurred. Leakage into
surrounding tissues will produce vesiculation of the skin and necrosis.
(b) Systemtic toxic effects
1. Acute toxicity.-Intra-arterial injection is always carried out under general
anaesthesia. A moderate fall in blood pressure invariably occurs following
injection and lasts approximately two minutes. Leakage into the soft tissues of
the head and neck is accompanied by oedema and occasionally, blistering of the
skin 6-8 hours after injection (Fig. 3). However in three patients the oedema
was unusually severe and accompanied by profound hypotension and death.
It is possible that the fatalitieswerethe result ofextreme histamine sensitivity and
S'4CHEMOTHERAPY IN HEAD AND NECK CANCER
pre-operative skin testing with 1/10,000 histamine diphosphate is now carried
out on all cases to be treated with this drug. In patients showing severe reaction
the dosage injected is greatly reduced.
2. Haematological effects.-In man given a dose of between 150 and 250 mg./
kg. the total white cell count will be depressed to its lowest value by the 14th day
(± 2 day) afterinjection. Values below 1000/c.mm. may be reached but recovery
has been complete in every case by the 21st-35th day. Since reducing the dosage
given intra-arterially to below 100 mg./kg. no total white cell count has fallen
below 1000/c.mm. Polymorphs are most severely affected and may fall to below
10 per cent of the total count. No buccal ulceration has occurred in any patient
even though total white counts of 500/c.mm. have been reached. The platelet
count is also depressed reaching a minimum figure of under 30,000/c.mm. in
severe cases. No serious bleeding has occurred and megakaryocytes are still
found in the marrow. Some reduction in haemoglobin levels is common after
repeated injections and blood transfusion may be necessary. Several patients
have survived three intra-arterial injections repeated at four weekly intervals with
no permanent damage to the haemopoietic system.
3. Tumour necrosis.-Unfortunately a dramatic tumour response may prove
fatal to the patient. Rapid necrosis ofthe cancer may lead to inhalation broncho-
pneumonia, uncontrollable haemorrhage or the production of a large tracheo-
oesophageal fistula. Where possible the intra-arterial injection is preceeded
by the excision of as much neoplasm as possible combined with ligature of poten-
tially dangerous blood vessels.
4. Alopecia.-Infusion of any alkylating agent into the branches of the
superficial temporal artery will produce unilateral alopecia. Digital pressure
is exerted over the main trunk ofthis vessel during the actual injection and mini-
mises the risk of this unpleasant side effect.
B. CYCLOPHOSPHAMIDE (N,N-BIS(/3-CHLOROETHYL)-N',O-PROPYLENE PHOSPHORIC
ACID DIAMIDE)
The N-phosphorylated nitrogen mustards, inactive precursors of the cytotoxic
mustards, are thought to be activated by phosphoramidases and phosphatases.
These enzymes are abundant in some malignant tumours and the development of
cyclophosphamide by Arnold and Bourseaux in 1958 was an attempt to create an
inactive transport form of an alkylating agent that would only become active
within the tumour cell. The drug is supplied in tablet form for oral use, and as
apowder to be dissolved insterile waterwhenintravenous or intra-arterial injection
is indicated.
Cyclophosphamide is unique amongst alkylating agents since, being stable in
aqueous solution and non-vesiculating, it can be given by almost any route. In
this series of patients the drug has been administered intra-venously, intra-
arterially, per orally and by direct injection into the tumour. Dosage has varied
from a maintenance level of 4 mg./kg./day to single intravascular injections of
60 mg./kg.
Toxicity
(a) Local toxic effects
Cyclophosphamide is very stable in vitro. No hydrolysis of the chlorine irons
has been detected in a neutral aqueous solution during an experimental period of
4
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two hours (Brock, 1958). Injections are well tolerated and no signs of irritation
of veins or arteries have been seen in patients of any age. The drug, when dis-
solved in normal saline, may be given intramuscularly, intra-peritoneally or
intra-pleurally-all without producing discomfort.
(b) Systemic toxic effects
Cyclophosphamide has been given in this series of patients either as daily
intravenous or oral doses, 4-8 mg./kg./day, or more recently, as single massive
intravascular injections, 40-60 mg./kg. Systemic toxic effects will therefore be
considered as resulting from daily dosage or single massive injections.
1. Nausea and vomiting
Daily dosage: 23/44 patients developed this unpleasant side effect at some
stage of their treatment. There appears to be no direct correlation between the
incidence of symptoms and either the level of daily dosage or total dosage. In
most cases, giving the total daily dose at night together with Avomine controlled
the nausea.
Single massive injections: 13/18 patients suffered severely from sickness
soon after injection. However if they were not affected by the first injection
then future injections with the same dosage did not produce nausea or vomiting.
2. Haematological effects.-The dosage of cyclophosphamide, given by any
route, is limited by its most serious side effect-bone marrow depression. This
is reflected, for practical purposes, in the peripheral blood picture. The total
white cell count is estimated at least thrice weekly during the time the patient is
in hospital. It is important to appreciate that the normal total white cell count
in the peripheral blood varies from 4000-11,000/c.mm. of blood (Whitby and
Britton, 1963). In addition the day to day variation in total white cell count in
any patient is considerable and we have placed more importance on the upward
and downward trend shown by successive counts than on any one individual
count. The error in estimation of the total white cell count is of the order of
± 20 per cent. As the accepted lower limit ofnormality is 4000/c.mm. the daily
dosage has been adjusted to produce a deliberate leucopenia of half this figure.
The lower the daily dosage the longer the total white cell count takes to show a
significant drop (Fig. 4) and in those patients where it proved impossible to main-
tain this leucopenia, there was no tumour response or alternatively " tumour
escape ". There have been no cases of buccal ulceration despite prolonged
eucopenia.
With single massive injections the time taken before a significant depression
ofthe total white cell count occurs is independent ofthe dose injected. However
the lowest count obtained is dependent on the total dosage given (Fig. 6) but varies
with each individual patient. No helpful information has been obtained from
differential counts and these have been discontinued.
EXPLANATION OF PLATE
FIG. 3. Blistering of the facial skin following intra-arterial ethoglucid.
FIG. 5.-(a) Severe alopecia after prolonged administration of cyclophosphamide.
(b) Histological section of the scalp of a patient with alopecia showing thin dermis and
absent bulbs of hair follicles.
FIG. 8. Fungating neoplasm of the maxilla.
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16/44 patients had platelet counts carried out when the total white cell count
was at its lowest level. 8/16 showed a level below 100,000/c.mm. but there has
been no instance of spontaneous bleeding and these estimations are no longer
carried out routinely. There is insufficient evidence to determine whether this
drug has a selective effect upon the haemoglobin concentration but regular estima-
tions are carried out and whole blood transfusions given when necessary.
3. Alopecia.-Noticeable loss of hair occurred in 22/44 patients receiving
daily dosage and 6/8 on single massive injections. However the degree ofalopecia
is impossible to determine accurately but no obvious relationship was found bet-
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FIG. 4.-Graph illustrating that the lower the daily dosage of cyclophosphamide the longer
the total white cell count takes to be depressed to 2000/c.mm.
ween the onset of hair loss and total dose of cyclophosphamide or depression of
total white cell count. Hair loss did appear to be greater in young women and
the hair growing at the vertex apparently less resistant to epilation. Neither the
eyebrows nor the lashes were involved (Fig. 5).
In the majority of cases surviving the early months of therapy, the hair re-
grew-in one patient with previously straight hair, the new growth was curly.
Wigs are provided when requested.
4. Cystitis.-7/44 patients receiving a total of over 10 g. by daily dosage,
developed a sterile cystitis. Eighteen patients on single massive injections had a
total of forty doses but only one developed cystitis. However the remaining
patients all had ahighfluid intakeforthetwenty-four hours followingthe injection
resulting in prolonged diuresis. The work of Mellett (1963) with tritium labelled
cyclophosphamide (C-3H) given to dogs at a dosage of 1 0mg./kg. by intravenous
injection, showed that 43 per cent ofthe total dose was excreted unchanged in theD. F. N. HARRISON AND W. N. TUCKER
urine within twenty-four hours. The sterile cystitis that commonly occurs after
prolonged or high dosage, may be an irritant effect of the high concentration of
cyclophosphamide, or a breakdown product, in the bladder. The passage of
large quantities of dilute urine secondary to high fluid intake appears to minimise
this unpleasant side effect.
METHODS OF ADMINISTRATION
Although the prognosis for patients with malignancies of the head and neck is
poor there are certain advantages to be gained by treating them with
chemotherapy.
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FIG. 6.-Graph showing that the lowest total white cell count is dependent upon total dosage.
Firstly the survival time, even of " failed " cases, can be measured in several
months and this gives the chemotherapeutic agent a reasonable opportunity of
producing tumour regression. Secondly, in most cases the tumour mass can be
easily seen and any change in size or appearance will be obvious. Biopsies can
be taken at regular intervals without inconveniencing the patient and necrotic
tumour tissue removed when necessary. Thirdly, use can be made of the fact
that most head and neck tumours are supplied by branches ofthe external carotid
artery. This vessel is readily available to the surgeon although previous radio-
therapy or radical surgery may have destroyed much of the normal regional
blood supply, thus reducing the efficacy of any intra-arterial chemotherapy.
Recent work by Goldacre and Sylven (1962) on "the access of blood borne
dyes to various tumour regions ", using experimental tumours, has substantiated
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our own experiences with Disulphine Blue (I.C.I.) in human neoplasms. Most of
the early, small tumours appear to be well vascularised and stained intensely.
However, the larger tumours frequently have a necrotic avascular area which
does not usually stain. Biopsy shows that in this area there remain cells which
histologically appear both malignant and viable-this has been confirmed experi-
mentally by Goldacre and Sylven (1962). Very occasionally these necrotic areas
are seen to stain slightly but the colour remains for several days after the dye has
disappeared from the rest of the body. We are in complete agreement with the
comment of Goldacre and Sylven, namely " the necrotic centre (of a tumour) is
an uneven dispersion of living tumour cells surviving almost anaerobically in a
medium of autolysed tumour tissue, which has no blood supply and exchanges
material only very slowly with the external living tissue ". It is quite possible
that the regrowth of tumour, which frequently occurs even after an initially
satisfactory response to chemotherapy, may be initiated by active malignant
cells lying in this avascular and untreated area.
It is our practice, whenever possible, to remove all necrotic tumour material
before commencing chemotherapy. This not only reduces the mass of tissue to
betreated, but afterinjection ofDisulphine Blue ensures that allthevisible tumour
is stained and thus vascularised. Ethoglucid possesses the attribute of easy
permeability and tumours may be seen to " wet " after intra-arterial infusion of
this drug. This is particularly important with those tumours whose blood supply
has been reduced because of previous treatment, or when avascular areas can not
be excised.
Local tumour resection will reduce the dangers of toxic absorption from mas-
sive tumour necrosis and minimise the risk of inhalation of necrotic growth when
the neoplasm is in close relation to the laryngeal inlet.
Arterial supply to the head and neck
The efficacy ofany chemotherapeutic agent depends to some extent on whether
it is possible to administer a large enough concentration to the tumour area.
In most tumours this is dependent upon the vascular supply and has been discus-
sed earlier in this paper. Most workers have used the main trunk ofthe external
carotid as the afferent artery but in this series of cases we have not hesitated to
infuse into both common and internal carotid arteries where necessary. No
deleterious effects upon the brain have been observed with ethoglucid or
cyclophosphamide.
In order to minimise leakage of the alkylating agent into the systemic circula-
tion, it is desirable to administer the smallest effective dosage ofthe drug. It is
therefore essential to isolate, where possible, the arterial supply to the tumour
area. This can only be carried out by surgical exposure of the upper inch of the
common carotid artery, the carotid bulb and the external carotid artery as high
as possible. Any branches leaving these vessels must be identified, and those not
required for infusion can be temporarily occluded. It is only by direct exposure
that the many variations in the branching of the external carotid artery can be
appreciated and care then taken to ensure that the cytotoxic agent is not infused
into unwanted tissues.
(a) In 16 per cent of cases the superior thyroid arises from the common carotid
artery. This vessel not only supplies the thyroid gland but gives offthe superior
laryngeal artery.
89D. F. N. HARRISON AND W. N. TUCKER
(b) The ascending pharyngeal, usually the smallest branch of the external
carotid artery, arises in 14 per cent of cases from the occipital artery and not from
the posterior surface ofthe external carotid. It supplies the pharynx, branches to
the palate and tonsil and the inferior tympanic branch to the middle ear.
(c) In 20 per cent of cases the lingual and facial arteries arise together from a
common stem. This is extremely important as the facial artery is much larger
and if both vessels are not identified then the greater proportion of any drug
introduced into the common trunk will pass into the face and not the tongue!
Occasionally the facial artery arises in common with the internal maxillary artery.
There is of course considerable overlapping of the vascular supply to most
regions of the head and neck and the problem is further complicated by previous
radiotherapy or surgery. After identification of the branches of the external
carotid artery, methylene blue is injected into the main vessel. This ensures
that:
(1) the blood supply to the tumour has been identified-verified by staining
of the tumour, and
(2) there is no staining of unwanted tissues. The latter is not always avoid-
able where the vessel supplying the tumour gives off branches which cannot be
occluded. Disulphine Blue is then injected-this is also a tracer dye but by
binding with plasma proteins produces a more intense and permanent colour.
This is of value for photography and post-operative inspection of the tumour-
it is excreted unchanged by the kidneys within 36 hours.
As yet no attempt has been made to expose the thyro-cervical trunk although
this will be essential if complete control of the vascular supply to larynx, thvroid
gland and musculature of the neck is to be gained.
Intra-arterial chemotherapy
There has been an embarrassing amount of literature relating to both tlle
technique and complications of indwelling arterial catheters (Nahum, 1962).
Arterial cannulation is essential with the antimetabolites but with the short actilng
alkylating agents a much simpler technique has been employed, reducing the
demands upon both nursing staff and hospital accommodation.
A. Ethoglucid.-The pharmacology of this bis-epoxide has been discussed
previously, sufficient to say that it is an active alkylating agent and has been
given intra-arterially in 30 patients in this series.
After confirmation that the blood supply to the tumour area has been isolated
ethoglucid, diluted with normal saline, is slowly infused through the same hypo-
dermic needle used previously to inject the tracer dye. Dilution of the cytotoxic
agent is necessary to prevent irritation and spasm of the vessel wall and varies
from four to ten times depending upon the size of the artery. If the needle has
been placed close to the carotid bulb, then 1 per cent procaine is introduced before
the ethoglucid to minimise the risk of a carotid sinus reflex.
At the completion of the infusion, the needle is removed and pressure applied
to the artery. The neck incision is then closed. During the administration of
the ethoglucid there is usually a temporary fall in blood pressure and ifthe tumour
is well vascularised, its surface may be seen to " wet " indicating that the drug
has permeated the whole tumour mass.
In the earlier cases the ethoglucid was given in doses of between 200 and 250
mg./kg. This has now been reduced to under 100 mg./kg. with equal tumour
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effect but marked reduction in toxic side effects. If necessary this dose may be
repeated, when any depression ofthe total white cell count has recovered. Within
twenty-four hours the main tumour mass will slough and this may be accom-
panied by haemorrhage, toxic absorption or even inhalation of necrotic debris.
The latter particular applies to lesions of the laryngo-pharynx. Some oedema
of surrounding tissues is invariable and follows leakage of the drug away from
the tumour or through non-occluded branches of the afferent vessel. Intra-
venous Phenergan 25 mg is now given immediately pre-operatively and appears
to prevent the severe, and often lethal oedema which occurred in some earlier
cases.
When tumours ofthetongue orlaryngo-pharynx arebeing treated apreliminary
tracheotomy is carried out as a precaution against severe laryngeal oedema. If
possible these patients are now treated with cyclophosphamide especially if
intra-dermal injection of 1/10,000 histamine diphosphate produces a marked
histamine sensitivity response. Samples are taken from the venous drainage
of the tumour (either the common facial or internal jugular vein) at regular inter-
vals during the infusion. This necessitates cannulatingthe vein andthe concentra-
tion of ethoglucid is estimated utilising a relatively simple technique (Fig. 2).
B. Cyclophosphamide.-Ten patients have been given this drug intra-arterially,
the afferent vessel to the tumour area being isolated using the same technique
as described for ethoglucid. Initially a standard dosage of 600 mg. dissolved in
300 ml. of normal saline was infused using a simple gravity feed. More recently
the dosage has been increased to 40 mg./kg. Infusion is now carried out by
means of a pump and the solution warmed to 400 C. to increase tumour blood flow.
Nahum and Rochlin (1963) have suggested body cooling to achieve a differential
temperature gradient between the tumour and systemic tissues, together with
a vasodilator such as papaverine hydrochloride in the warmed infusate. This
would appear to be a logical approach to this problem and it is intended to modify
our technique in future cases. Sloughing of the tumour mass occurs within
twenty-four hours but is not accompanied by oedema of surrounding tissues.
ASystemic Chemotherapy
Unfortunately in many patients previous treatment will have radically
affected the vascular anatomy of the head and neck making intra-arterial chemo-
therapy impracticable. Systemic metastases or widespread local extension may
also indicate that the most effective treatment is by the intravenous or oral
route.
(a) Low dosage maintenance therapy.-In this regime, employed in earlier cases
but now replaced by single massive intravenous therapy, cyclophosphamide was
given in daily intravenous injections of 8 mg./kg./day, until the total white cell
count had fallen to 2000/c.mm. The drug was then given by mouth in sufficient
quantity-usually 4 mg./kg./day to maintain this leucopenia. The patient was
seen at regular intervals for white cell counts and appraisal of tumour response,
and treatment continued in successful cases for at least a year or until tumour
" escape " occurred. Nausea was a frequent complication but could be controlled
by anti-emetics or by taking the daily dose at night together with a mild hypnotic.
(b) High dose therapy.-Single intravenous injections of 40-60 mg./kg. are
given and repeated when the leucopenia which follows has recovered (Fig. 7).
This large dose produces severe nausea and vomiting for twelve hours and patients
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are admitted to hospital for the day. Fluid intake is increased for several days
and this avoids the unpleasant chemical cystitis which invariably occurs secondary
to the excretion of a high concentration of cyclophosphamide. Clinical results
utilising this technique have been most rewarding especially in cases previously
untreated.
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FiG. 7.-Effect of repeated single massive intravenous injections of cyclophosphamide
on the total white cell count. Case 66.
RESULTS OF TREATMENT
Any attempt to select patients for chemotherapy on purely ethical grounds
is in our opinion, not only impossible but unrealistic. In this series no patient
has been refused treatment, no matter how extensive the primary lesion or how
widespread the metastases.
A positive biopsy was obtained in every case (Table I), 84 per cent being
squamous carcinomata. It is our impression that the degree of differentiation
ofthese tumours plays little part in determining the tumour response to ethoglucid
or cyclophosphamide. Many investigators have attempted to assess tumour
response to chemotherapy by devious, intricate and imaginative techniques. The
majority of tumours encountered in this series have been extensive and the
patients so desperate that our prime aim has been to produce at the very least,
symptomatic relief, and at best a return to normal life. Results tabulated in
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Table I have been graded on clinical and sociological findings and not on macro-
scopical and radiological impressions.
Grade O-No effect
In 26 patients (32 per cent) no worthwhile improvement was produced-this
included all cases dying within one month of commencing treatment. Most of
these patients were elderly and either had extensive disease with metastases or
had previously received treatment by radical surgery and radiotherapy. No case
with a local recurrence of growth after radical dissection of glands of the neck
showed any improvement with systemic chemotherapy.
Grade 1-Symptomatic relief
Twenty-four patients (30 per cent) were recorded as showing symptomatic
relief. This grading defies accurate definition but includes any case showing for at
least two months, reduction in tumour size, cessation ofpain or the return ofsome
previously impaired function. In 3 cases the rate of growth of the tumour was
controlled for over six months and it was only on the cessation of treatment that
rapid growth ofthe neoplasm resulted in death ofthe patient. No case was able
to return home for more than a few days.
Grade 2-Home with limited activity
In 21 cases (26 per cent) improvement was enough to enable the patient to
return home. Limited medical and nursing care was still necessary in most
cases but the patient was encouraged, and able, to live as active a life as the indi-
vidual circumstances allowed. Every case eventually returned to hospital and the
period of home-care varied from two to eighteen months. To some extent these
patients became once again, the responsibility of the family doctor although
regular visits to hospital for blood counts and tumour appraisal were insisted
upon whenever feasible. We consider this group of patients to have been the
most rewarding. All were incurable by present day techniques and the most that
chemotherapy could offer was to reduce the size ofthe tumour and relieve pain or
toxicity long enough to enable the patients to return to their home without
dependence upon relatives or friends. With very extensive tumours in unfavour-
able sites such as the nasopharynx, middle ear and ethmoidal labyrinth, this is
probably the greatest improvement that will be possible in the foreseeable future.
Grade 3-Return to normal life
The 9 patients (12 per cent) placed in this group all showed disappearance of
their tumours whilst under treatment. Two have died from other causes and
histological examination ofpost mortem material revealed no residual malignancy.
All of the remaining patients are now at home living completely normal lives.
Case 5 and Case 6 first started chemotherapy twenty-two months ago and Case
7 twenty months ago. Re-evaluation ofthis small group ofpatients has revealed
no obvious explanation for their exceptional good response to treatment.
CAUSES OF DEATH
Every patient accepted for chemotherapy has been re-admitted if requested
during the terminal stage oftheir disease. Consequently considerable experience
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has been gained not only of deaths directly attributable to chemotherapy but
also of the natural history of advanced cancer of the head and neck.
(a) Age
Sixty per cent of the patients treated were aged 60 years or over, although
ages varied from 14 months to 82 years. Many were extremely ill and feeble as
a result of malnutrition, toxaemia or concurrent cardiovascular and respiratory
disease. Treatment was never refused on the grounds of age alone although
several successful tumour responses were followed by gradual deterioration and
death a few weeks later.
(b) Extension of the tumour
Even a rapid increase in the rate of growth of tumours of the head and neck
rarely results in immediate death unless a major blood vessel is involved or dura
exposed with subsequent meningitis. Tumours, especially of the maxilla, may
grow to considerable proportions causing the unfortunate patient great distress
but without producing death for many months (Fig. 8). The passage of feeding
and tracheotomy tubes provides the patient with food and air but may only pro-
long an already unhappy existence.
(c) Destruction of tumour
Inhalation bronchopneumonia frequently accompanies both natural and
chemotherapeutic destruction of large tumours of the laryngo-pharynx. Where
the tumour has replaced a party wall, as exists between trachea and cervical
oesophagus, then destruction of the growth may result in a large dehiscence in-
compatable with life. Two patients died as a direct result of infection through
such a defect although subsequent post mortem examination showed almost
complete tumour destruction.
(d) Overwhelming infection
We have recently been concerned over the apparent lack of resistance to
infection shown by a few patients receiving long term systemic cyclophosphamide.
After a total dosage exceeding 10 g. three patients succumbed to overwhelming
chest infections. Leucopenia is unlikely to have been the underlying factor as
this is deliberately produced and maintained in most cases. It is our impression
that these patients had lost their power of immune body response, perhaps
secondary to cyclophosphamide induced atrophy of the reticulo-endothelial
system.
With the exception of two cases, every patient in this series dying in hospital
has had a post mortem examination carried out. This has provided valuable
information as to the effect of chemotherapy on head and neck tumours-paths
of extension ofuncontrolled neoplasms and the incidence ofunsuspected systemic
metastases. The data obtained from this investigation, based on 42 post mortem
examinations, will be incorporated into a future paper.
DISCUSSION
There is considerable confusion as to therightful role that chemotherapy should
play in the management of cancer of the head and neck. Chemotherapeutic
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success depends largely on concentrating enough of the active agent within the
tumour area-but without producing fatal systemic side effects. Although
avascular necrotic tumour tissue can be excised, previous radical surgery or
radiotherapy destroys much of the regional blood supply making it impossible to
bring enough active cytotoxic agent into close contact with the neoplastic cell.
However it would be difficult at present, to justify the thesis that all cancers of
the head and neck should be treated primarily by chemotherapy.
The majority of patients reviewed in this paper had already failed to respond
to orthodox treatment and faced an often prolonged period of misery and dis-
ability before finally succumbing to haemorrhage or bronchopneumonia. It is
our contention that the practical value of a chemotherapeutic agent can only be
determined by its use in cases of human cancer. The changing from one pre-
paration to another, without a properly conducted clinical trial, is to be stronglv
deprecated. Only recently have we felt reasonably assured of our ability to
effectively administer the two alkylating agents described in this paper.
Eight patients, with previously untreated neoplasms have received chemo-
therapy as their primary therapy. In each case the prognosis was poor because
of advanced age, systemic disease etc. However the immediate response has
been dramatic and it is intended to use this form of therapy in further selected
cases. The potentialities of effective chemotherapy are legion but it is wise to
remember that as yet the available cytotoxic agents are only of limited value in
head and neck cancer. Our experience has shown that both ethoglucid and
cyclophosphamide, when administered selectively, can offer considerable relief
to patients with advanced cancer of the head and neck, providing vascular supply
remains. Lymph gland metastases, particularly in a neck previously irradiated
or operated upon, presents an almost insuperable problem-as does the verv
advanced neoplasm.
If the extremely poor prognosis of malignant conditions of the head and neck
is to be improved then our attention must be turned towards the diagnosis and
management of the early lesion. When surgical excision is appropriate this could
be combined with single intravenous injections of cyclophosphamide 40 mg./kg.
it is fully appreciated however that the rationale of this proposal could not be
substantiated or refuted for many years. An attempt might also be made to
prevent dissemination of tumour cells by intra-arterial injection of ethoglucid
before surgical excision. Our own search for circulating cancer cells in the re-
gional veins has proved unsuccessful in this series of cases. Both these proposals
are now implemented in our management of new cases of head and neck cancer.
Enthusiastic attempts to improve the prognosis and well-being of these un-
fortunate patients is praiseworthy but may be unjustifiable when resulting in
severe side effects or suppurating deformities. The selection of both drugs and
techniques described in this paper was carried out with these principles in mind
and the result only termed successful when the patient returned home, able to
live a normal existence.
SUMMARY
Eighty cases of advanced cancer of the head and neck have been treated with
intra-arterial or systemic chemotherapy over the past two years. Two alkylat-
ing agents, ethoglucid and cyclophosphamide have been used and their pharma-
cology and methods of administration is discussed in detail. Nine patients96 D. F. N. HARRISON AND W. N. TUCKER
(12 per cent) obtained complete regression oftheir tumours, three remaining alive
and well at the present time-22 months after commencing chemotherapy.
Some of the factors which may be important in influencing the efficacy of chemo-
therapy are examined together with suggestions for improving the prognosis
in early neoplasms of the head and neck.
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